Lataa...
Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
BACKGROUND: Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical costs of BTs treatment have been investigated in multiple foreign studies in r...
Tallennettuna:
| Julkaisussa: | BMC Dermatol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6042444/ https://ncbi.nlm.nih.gov/pubmed/29996929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12895-018-0074-0 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|